leflunomide has been researched along with Adverse Drug Event in 12 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with leflunomide was well tolerated with mostly low-grade adverse events." | 2.75 | The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. ( Adelsberger, JW; Ciccone, EJ; DeGrezia, M; DerSimonian, R; Higgins, J; Read, SW; Rehm, C; Sereti, I; Starling, JM, 2010) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Devarbhavi, H | 1 |
| Ghabril, M | 1 |
| Barnhart, H | 1 |
| Patil, M | 1 |
| Raj, S | 1 |
| Gu, J | 1 |
| Chalasani, N | 1 |
| Bonkovsky, HL | 1 |
| Zewail, MB | 1 |
| El-Gizawy, SA | 1 |
| Asaad, GF | 1 |
| Shabana, ME | 1 |
| El-Dakroury, WA | 1 |
| El-Sheikh, SMA | 1 |
| Abd El-Alim, AEF | 1 |
| Galal, AAA | 1 |
| El-Sayed, RG | 1 |
| El-Naseery, NI | 1 |
| Sardana, K | 1 |
| Gupta, A | 1 |
| Gupta, PK | 1 |
| Read, SW | 1 |
| DeGrezia, M | 1 |
| Ciccone, EJ | 1 |
| DerSimonian, R | 1 |
| Higgins, J | 1 |
| Adelsberger, JW | 1 |
| Starling, JM | 1 |
| Rehm, C | 1 |
| Sereti, I | 1 |
| Mittal, N | 1 |
| Sharma, A | 1 |
| Jose, V | 1 |
| Mittal, R | 1 |
| Wanchu, A | 1 |
| Bambery, P | 1 |
| Holden, WL | 1 |
| Scarazzini, LJ | 1 |
| Davis, WM | 1 |
| Waters, IW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Longitudinal Study of Drug-and CAM-Induced Liver Injury[NCT00345930] | 4,000 participants (Anticipated) | Observational | 2004-09-30 | Recruiting | |||
| A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Leflunomide on HIV-1 Associated Immune Proliferation In Vivo[NCT00101374] | Phase 1 | 41 participants (Actual) | Interventional | 2005-01-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for leflunomide and Adverse Drug Event
| Article | Year |
|---|---|
The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug-Related Side Effects and Adverse | 2010 |
11 other studies available for leflunomide and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.
Topics: Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Drug-Relate | 2022 |
Chitosan coated clove oil-based nanoemulsion: An attractive option for oral delivery of leflunomide in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Chitosan; Clove Oil; Drug-Related Side Effects | 2023 |
Anti-arthritic effect of β-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Arthritis, Experi | 2019 |
Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.
Topics: Alopecia Areata; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Leflunomide | 2019 |
Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Th | 2012 |
Postmarketing surveillance for drug safety.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug-Related Side Effects and Adverse Reactions; Humans; Is | 2004 |
A new-drug roundup.
Topics: Acetates; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ant | 1999 |